Grants and Funding
NIH Human Embryonic Stem Cell Registry
Research Using These Lines is Eligible for NIH Funding

The lines listed below are eligible for use in NIH funded research. Those lines that carry disease-specific mutations are noted as such under the line name.

For guidance regarding applications proposing to use hESC see: NIH Guide Notices NOT-OD-10-020 and NOT-OD-10-029.

Eligible Lines: 
Sorted by:
Date/Time:
283  (in 123 Submissions)
Approval Date (descending), Organization Name, Cell Line Name
09/18/2014 at 04:03 AM
Cell Line NIH Registration
Number

(Use for NIH Applications *)
Provider Submitting
Organization
Approval
Date
Descending Sort
HUES 71
(see details)
0281 Eggan Lab Harvard University 07/31/2014
HUES 72
(see details)
0282 Eggan Lab Harvard University 07/31/2014
HUES 73
(see details)
0283 Eggan Lab Harvard University 07/31/2014
HUES 75
(see details)
0280 Eggan Lab Harvard University 07/31/2014
UM33-4
(see details)
0279 Gary D. Smith / University of Michigan University of Michigan 04/09/2014
UM77-2
(see details)
0278 Gary D. Smith / University of Michigan University of Michigan 04/09/2014
UM63-1
(see details)
0277 Gary D. Smith/University of Michigan University of Michigan 04/09/2014
UM89-1 PGD; disease-specific mutation
(see details)
0276 Gary D. Smith/University of Michigan University Of Michigan 04/09/2014
UM59-2 PGD; disease-specific mutation
(see details)
0275 Gary D. Smith/University of Michigan University of Michigan 04/09/2014
KCL039
(see details)
0274 Dusko Ilic, King's College London King's College London 03/25/2014
KCL041; abnormal karyotype/disease-specific mutation
(see details)
0273 Dusko Ilic, King's College London King's College London 03/25/2014
KCL040
(see details)
0272 Dusko Ilic, King's College London King's College London 03/25/2014
KCL020
(see details)
0271 Dusko Ilic, King's College London King's College London 03/25/2014
KCL019
(see details)
0270 Dusko Ilic, King's College London King's College London 03/25/2014
KCL037
(see details)
0269 Dusko Ilic, King's College London King's College London 03/25/2014
KCL032
(see details)
0266 Dusko Ilic, King's College London King's College London 03/25/2014
KCL033
(see details)
0267 Dusko Ilic, King's College London King's College London 03/25/2014
KCL034
(see details)
0268 Dusko Ilic, King's College London King's College London 03/25/2014
KCL038
(see details)
0265 Dusko Ilic, King's College London King's College London 03/25/2014
KCL022
(see details)
0264 Dusko Ilic, King's College London King's College London 03/25/2014
KCL031
(see details)
0263 Dusko Ilic, King's College London King's College London 03/25/2014
KCL023
(see details)
0262 Dusko Ilic, King's College London King's College London 03/25/2014
GENEA077; disease-specific mutation
(see details)
0261 Genea Biocells Genea Biocells 01/29/2014
GENEA078 ; disease-specific mutation
(see details)
0252 Genea Biocells Genea Biocells 01/29/2014
GENEA079 ; disease-specific mutation
(see details)
0253 Genea Biocells Genea Biocells 01/29/2014
GENEA080 ; disease-specific mutation
(see details)
0254 Genea Biocells Genea Biocells 01/29/2014
GENEA081 ; disease-specific mutation
(see details)
0255 Genea Biocells Genea Biocells 01/29/2014
GENEA083; disease-specific mutations, abnormal karyotype
(see details)
0256 Genea Biocells Genea Biocells 01/29/2014
GENEA084 ; disease-specific mutation
(see details)
0257 Genea Biocells Genea Biocells 01/29/2014
GENEA086 ; disease-specific mutation
(see details)
0258 Genea Biocells Genea Biocells 01/29/2014
GENEA087 ; disease-specific mutation
(see details)
0259 Genea Biocells Genea Biocells 01/29/2014
GENEA088 ; disease-specific mutation
(see details)
0260 Genea Biocells Genea Biocells 01/29/2014
GENEA082 ; disease-specific mutation, abnormal karyotype
(see details)
0251 Genea Biocells Genea Biocells 01/29/2014
GENEA085 ; disease-specific mutation
(see details)
0250 Genea Biocells Genea Biocells 01/29/2014
GENEA089; disease-specific mutations
(see details)
0247 Genea Biocells Genea Biocells 01/29/2014
GENEA097; disease-specific mutations
(see details)
0248 Genea Biocells Genea Biocells 01/29/2014
GENEA098; disease-specific mutations
(see details)
0249 Genea Biocells Genea Biocells 01/29/2014
GENEA090; disease-specific mutations
(see details)
0245 Genea Biocells Genea Biocells 01/29/2014
GENEA091; disease-specific mutations
(see details)
0246 Genea Biocells Genea Biocells 01/29/2014
GENEA096; disease-specific mutations
(see details)
0244 Genea Biocells Genea Biocells 01/29/2014
KCL043; disease-specific mutation
(see details)
0243 Dusko Ilic, King's College London King's College London 12/23/2013
KCL042; disease-specific mutation
(see details)
0242 Dusko Ilic, King's College London King's College London 12/23/2013
KCL036; disease-specific mutation
(see details)
0241 Dusko Ilic, King's College London King's College London 12/23/2013
NYUES10
(see details)
0240 Christoph Hansis, MD, PhD New York University School of Medicine 12/23/2013
NYUES9
(see details)
0239 Christoph Hansis, MD, PhD New York University School of Medicine 12/23/2013
NYUES8
(see details)
0238 Christoph Hansis, MD, PhD New York University School of Medicine 12/23/2013
NYUES11; abnormal karyotype
(see details)
0236 Christoph Hansis, MD, PhD New York University School of Medicine 12/23/2013
NYUES13
(see details)
0237 Christoph Hansis, MD, PhD New York University School of Medicine 12/23/2013
NYUES12
(see details)
0235 Christoph Hansis, MD, PhD New York University School of Medicine 12/23/2013
GENEA052
(see details)
0234 Genea Biocells Genea Biocells 09/30/2013
GENEA057
(see details)
0233 Genea Biocells Genea Biocells 09/30/2013
GENEA042
(see details)
0231 Genea Biocells Genea Biocells 09/30/2013
GENEA043
(see details)
0232 Genea Biocells Genea Biocells 09/30/2013
GENEA047
(see details)
0230 Genea Biocells Genea Biocells 09/30/2013
GENEA015
(see details)
0228 Genea Biocells Genea Biocells 09/30/2013
GENEA016
(see details)
0229 Genea Biocells Genea Biocells 09/30/2013
KCL030; disease-specific mutation
(see details)
0226 Dusko Ilic, King's College London King's College London 09/19/2013
KCL035; disease-specific mutation
(see details)
0227 Dusko Ilic, King's College London King's College London 09/19/2013
KCL029; disease-specific mutation
(see details)
0225 Dusko Ilic, King's College London King's College London 09/19/2013
KCL027; disease-specific mutation
(see details)
0223 Dusko Ilic, King's College London King's College London 09/19/2013
KCL028; disease-specific mutation
(see details)
0224 Dusko Ilic, King's College London King's College London 09/19/2013
KCL026; disease-specific mutation
(see details)
0222 Dusko Ilic, King's College London King's College London 09/19/2013
KCL024; disease-specific mutation
(see details)
0220 Dusko Ilic, King's College London King's College London 09/19/2013
KCL025; disease-specific mutation
(see details)
0221 Dusko Ilic, King's College London King's College London 09/19/2013
KCL021; disease-specific mutation
(see details)
0219 Dusko Ilic, King's College London King's College London 09/19/2013
KCL018; disease-specific mutation
(see details)
0218 Dusko Ilic, King's College London King's College London 09/19/2013
KCL015; disease-specific mutation
(see details)
0215 Dusko Ilic, King's College London King's College London 09/19/2013
KCL016; disease-specific mutation
(see details)
0216 Dusko Ilic, King's College London King's College London 09/19/2013
KCL017; disease-specific mutation
(see details)
0217 Dusko Ilic, King's College London King's College London 09/19/2013
KC013; disease-specific mutation
(see details)
0214 Dusko Ilic, King's College London King's College London 09/19/2013
KCL012; disease-specific mutation
(see details)
0213 Dusko Ilic, King's College London King's College London 09/19/2013
KCL011
(see details)
0212 Dusko Ilic, King's College London King's College London 09/19/2013
WCMC-37; disease-specific mutation
(see details)
0211 Weill Cornell Medical College- Nikica Zaninovic, PhD and Zev Rosenwaks, MD Joan & Sanford I. Weill Medical College of Cornell University 06/27/2013
CR-4
(see details)
0210 Rick A. Wetsel, Ph.D. University of Texas Hlth Sci Ctr at Houston 05/29/2013
UM22-2
(see details)
0209 Gary D. Smith/University of Michigan University of Michigan 03/26/2013
UM57-1 PGD; disease-specific mutation
(see details)
0208 Gary D. Smith/University of Michigan University of Michigan 03/26/2013
HS799; disease-specific mutation
(see details)
0207 Karolinska Institute Karolinska Institute 03/18/2013
I3 (TE03)
(see details)
0204 Technion R&D foundation Technion R&D Foundation 03/18/2013
I4 (TE04)
(see details)
0205 Technion R&D foundation Technion R&D Foundation 03/18/2013
I6 (TE06)
(see details)
0206 Technion R&D foundation Technion R&D Foundation 03/18/2013
HS346
(see details)
0201 Karolinska Institute Karolinska Institute 03/18/2013
HS401
(see details)
0202 Karolinska Institute Karolinska Institute 03/18/2013
HS420
(see details)
0203 Karolinska Institute Karolinska Institute 03/18/2013
GENEA065; Disease-specific mutation
(see details)
0200 Genea Biocells Genea Biocells 01/08/2013
GENEA058; Disease-specific mutation
(see details)
0199 Genea Biocells Genea Biocells 01/08/2013
WA25
(see details)
0196 WiCell Research Institute WiCell Research Institute 12/14/2012
WA26
(see details)
0197 WiCell Research Institute WiCell Research Institute 12/14/2012
WA27
(see details)
0198 WiCell Research Institute WiCell Research Institute 12/14/2012
HUES PGD 2; possible disease-specific mutation
(see details)
0195 Eggan Lab Harvard University 12/14/2012
GENEA062; disease-specific mutation
(see details)
0187 Genea Biocells Genea Biocells 12/14/2012
GENEA063; disease-specific mutation
(see details)
0188 Genea Biocells Genea Biocells 12/14/2012
GENEA066; disease-specific mutation
(see details)
0189 Genea Biocells Genea Biocells 12/14/2012
GENEA067; disease-specific mutation
(see details)
0190 Genea Biocells Genea Biocells 12/14/2012
GENEA071; disease-specific mutation
(see details)
0191 Genea Biocells Genea Biocells 12/14/2012
GENEA072; disease-specific mutation
(see details)
0192 Genea Biocells Genea Biocells 12/14/2012
GENEA073; disease-specific mutation
(see details)
0193 Genea Biocells Genea Biocells 12/14/2012
GENEA074; disease-specific mutation
(see details)
0194 Genea Biocells Genea Biocells 12/14/2012
UCLA 11
(see details)
0185 Steven Peckman University of California, Los Angeles 11/20/2012
UCLA 12
(see details)
0186 Steven Peckman University of California, Los Angeles 11/20/2012
GENEA049; disease-specific mutation
(see details)
0183 Genea Biocells Genea Biocells 11/02/2012
GENEA050; disease-specific mutation
(see details)
0184 Genea Biocells Genea Biocells 11/02/2012
GENEA069; disease-specific mutation
(see details)
0181 Genea Biocells Genea Biocells 10/05/2012
GENEA070; disease-specific mutation
(see details)
0182 Genea Biocells Genea Biocells 10/05/2012
GENEA046; disease-specific mutation
(see details)
0180 Genea Biocells Genea Biocells 10/05/2012
HUES PGD 10
(see details)
0179 Eggan Lab Harvard University 09/24/2012
HUES 69
(see details)
0178 HSCI iPS Core Harvard University 08/07/2012
HUES 68
(see details)
0176 HSCI iPS Core Harvard University 07/09/2012
HUES 70
(see details)
0177 HSCI iPS Core Harvard University 07/09/2012
GENEA059; disease-specific mutation
(see details)
0175 Genea Biocells Genea Biocells 07/09/2012
GENEA018; disease-specific mutation
(see details)
0169 Genea Biocells Genea Biocells 06/20/2012
GENEA024; disease-specific mutation
(see details)
0170 Genea Biocells Genea Biocells 06/20/2012
GENEA040; disease-specific mutation
(see details)
0171 Genea Biocells Genea Biocells 06/20/2012
GENEA060; disease-specific mutation
(see details)
0172 Genea Biocells Genea Biocells 06/20/2012
GENEA061; disease-specific mutation
(see details)
0173 Genea Biocells Genea Biocells 06/20/2012
GENEA064; disease-specific mutation
(see details)
0174 Genea Biocells Genea Biocells 06/20/2012
GENEA017; disease-specific mutation
(see details)
0166 Genea Biocells Genea Biocells 06/20/2012
GENEA041; disease-specific mutation
(see details)
0167 Genea Biocells Genea Biocells 06/20/2012
GENEA068; disease-specific mutation
(see details)
0168 Genea Biocells Genea Biocells 06/20/2012
UM29-2 PGD; disease-specific mutation
(see details)
0164 Gary D. Smith/University of Michigan University of Michigan 06/18/2012
UM29-3 PGD; disease-specific mutation
(see details)
0165 Gary D. Smith/University of Michigan University of Michigan 06/18/2012
UM14-1
(see details)
0162 Gary D. Smith/University of Michigan University of Michigan 05/31/2012
UM14-2
(see details)
0163 Gary D. Smith/University of Michigan University of Michigan 05/31/2012
UM15-4 PGD; disease-specific mutation
(see details)
0161 University of Michigan, Gary D. Smith University of Michigan 05/31/2012
UM17-1 PGD; disease-specific mutation
(see details)
0160 Gary D. Smith/University of Michigan University of Michigan 05/31/2012
NMR-1
(see details)
0159 Rick A. Wetsel, Ph.D. University of Texas Hlth Sci Ctr Houston 05/31/2012
HUES 42
(see details)
0157 HSCI iPS Core Harvard University 05/31/2012
HUES 44
(see details)
0158 HSCI iPS Core Harvard University 05/31/2012
Elf1
(see details)
0156   University of Washington 05/15/2012
UM38-2 PGD; disease-specific mutation
(see details)
0155 Gary D. Smith, University of Michigan University of Michigan 05/14/2012
UM9-1PGD; disease-specific mutation
(see details)
0154 Gary D. Smith, University of Michigan University of Michigan 05/14/2012
UM11-1PGD; disease-specific mutation
(see details)
0153 Gary D. Smith, University of Michigan University of Michigan 04/12/2012
GENEA002
(see details)
0151 Genea Biocells Genea Biocells 03/20/2012
GENEA048; abnormal karyotype
(see details)
0152 Genea Biocells Genea Biocells 03/20/2012
HUES PGD 15; possible disease-specific mutation
(see details)
0149 Eggan Lab Harvard University 02/24/2012
HUES PGD 16; disease-specific mutation
(see details)
0150 Eggan Lab Harvard University 02/24/2012
HUES PGD 1; disease-specific mutation
(see details)
0148 Eggan Lab Harvard University 02/24/2012
UM4-6
(see details)
0147 Gary D. Smith, University of Michigan University of Michigan 02/02/2012
UCLA 10
(see details)
0146 Steven Peckman University of California, Los Angeles 01/12/2012
UCLA 7; disease-specific mutation/abnormal karyotype
(see details)
0143 Steven Peckman University of California, Los Angeles 01/12/2012
UCLA 8
(see details)
0144 Steven Peckman University of California, Los Angeles 01/12/2012
UCLA 9
(see details)
0145 Steven Peckman University of California, Los Angeles 01/12/2012
MEL-1
(see details)
0139 StemCore, Stem Cells Ltd University of Queensland 12/22/2011
MEL-2
(see details)
0140 StemCore, Stem Cells Ltd University of Queensland 12/22/2011
MEL-3
(see details)
0141 StemCore, Stem Cells Ltd University of Queensland 12/22/2011
MEL-4
(see details)
0142 StemCore, Stem Cells Ltd University of Queensland 12/22/2011
CA1
(see details)
0137 Andras Nagy Mt Sinai Hosp-Samuel Lunenfeld Research Institute 12/12/2011
CA2
(see details)
0138 Andras Nagy Mt Sinai Hosp-Samuel Lunenfeld Research Institute 12/12/2011
HUES PGD 14; disease-specific mutation
(see details)
0136 Eggan Lab Harvard University 10/11/2011
CSES18
(see details)
0135 Juan Carlos Biancotti Cedars-Sinai Medical Center 09/27/2011
CSES5; abnormal karyotype
(see details)
0133 Juan Carlos Biancotti Cedars-Sinai Medical Center 09/27/2011
CSES6; abnormal karyotype
(see details)
0134 Juan Carlos Biancotti Cedars-Sinai Medical Center 09/27/2011
ESI-051
(see details)
0131 BioTime, Inc. BioTime, Inc. 08/18/2011
ESI-053
(see details)
0132 BioTime, Inc. BioTime, Inc. 08/18/2011
ESI-049
(see details)
0130 BioTime, Inc. BioTime, Inc. 08/18/2011
ESI-035
(see details)
0129 BioTime, Inc. BioTime, Inc. 08/18/2011
RNJ18; disease-specific mutation
(see details)
0128 Reprogenetics, LLC Reprogenetics, LLC 06/16/2011
RNJ19; disease-specific mutation
(see details)
0126 Reprogenetics, LLC Reprogenetics, LLC 06/16/2011
RNJ20; disease-specific mutation
(see details)
0127 Reprogenetics, LLC Reprogenetics, LLC 06/16/2011
HAD-C 100
(see details)
0123 Benjamin E. Reubinoff Hadassah Hebrew University Medical Center 06/16/2011
HAD-C 102
(see details)
0124 Benjamin E. Reubinoff Hadassah Hebrew University Medical Center 06/16/2011
HAD-C 106
(see details)
0125 Benjamin E. Reubinoff Hadassah Hebrew University Medical Center 06/16/2011
CSES11; abnormal karyotype
(see details)
0110 Juan Carlos Biancotti Cedars-Sinai Medical Center 06/10/2011
CSES12; abnormal karyotype
(see details)
0111 Juan Carlos Biancotti Cedars-Sinai Medical Center 06/10/2011
CSES13; abnormal karyotype
(see details)
0112 Juan Carlos Biancotti Cedars-Sinai Medical Center 06/10/2011
CSES14; abnormal karyotype
(see details)
0113 Juan Carlos Biancotti Cedars-Sinai Medical Center 06/10/2011
CSES15
(see details)
0114 Juan Carlos Biancotti Cedars-Sinai Medical Center 06/10/2011
CSES17
(see details)
0115 Juan Carlos Biancotti Cedars-Sinai Medical Center 06/10/2011
CSES19
(see details)
0116 Juan Carlos Biancotti Cedars-Sinai Medical Center 06/10/2011
CSES2
(see details)
0106 Juan Carlos Biancotti Cedars-Sinai Medical Center 06/10/2011
CSES20; abnormal karyotype
(see details)
0117 Juan Carlos Biancotti Cedars-Sinai Medical Center 06/10/2011
CSES21; abnormal karyotype
(see details)
0118 Juan Carlos Biancotti Cedars-Sinai Medical Center 06/10/2011
CSES22; abnormal karyotype
(see details)
0119 Juan Carlos Biancotti Cedars-Sinai Medical Center 06/10/2011
CSES23; abnormal karyotype
(see details)
0120 Juan Carlos Biancotti Cedars-Sinai Medical Center 06/10/2011
CSES24; abnormal karyotype
(see details)
0121 Juan Carlos Biancotti Cedars-Sinai Medical Center 06/10/2011
CSES25
(see details)
0122 Juan Carlos Biancotti Cedars-Sinai Medical Center 06/10/2011
CSES4
(see details)
0107 Juan Carlos Biancotti Cedars-Sinai Medical Center 06/10/2011
CSES7
(see details)
0108 Juan Carlos Biancotti Cedars-Sinai Medical Center 06/10/2011
CSES8; abnormal karyotype
(see details)
0109 Juan Carlos Biancotti Cedars-Sinai Medical Center 06/10/2011
WA15
(see details)
0096 WiCell Research Institute WiCell Research Institute 06/09/2011
WA16; disease-specific mutation/abnormal karyotype
(see details)
0097 WiCell Research Institute WiCell Research Institute 06/09/2011
WA17
(see details)
0098 WiCell Research Institute WiCell Research Institute 06/09/2011
WA18
(see details)
0099 WiCell Research Institute WiCell Research Institute 06/09/2011
WA19
(see details)
0100 WiCell Research Institute WiCell Research Institute 06/09/2011
WA20
(see details)
0101 WiCell Research Institute WiCell Research Institute 06/09/2011
WA21
(see details)
0102 WiCell Research Institute WiCell Research Institute 06/09/2011
WA22
(see details)
0103 WiCell Research Institute WiCell Research Institute 06/09/2011
WA23
(see details)
0104 WiCell Research Institute WiCell Research Institute 06/09/2011
WA24
(see details)
0105 WiCell Research Institute WiCell Research Institute 06/09/2011
HUES PGD 11; disease-specific mutation
(see details)
0094 Eggan Lab Harvard University 06/07/2011
HUES PGD 12; disease-specific mutation
(see details)
0095 Eggan Lab Harvard University 06/07/2011
ESI-014
(see details)
0092   BioTime, Inc. 06/02/2011
ESI-017
(see details)
0093 BioTime, Inc. BioTime, Inc. 06/02/2011
HUES PGD 3; disease-specific mutation
(see details)
0091 Eggan Lab Harvard University 03/15/2011
HUES PGD 13; disease-specific mutation
(see details)
0090 Eggan Lab Harvard University 03/15/2011
UCLA 4
(see details)
0087 Steven Peckman University of California Los Angeles 02/03/2011
UCLA 5
(see details)
0088 Steven Peckman University of California Los Angeles 02/03/2011
UCLA 6
(see details)
0089 Steven Peckman University of California Los Angeles 02/03/2011
SA001
(see details)
0085 Cellartis AB Cellartis AB 12/17/2010
SA002; abnormal karyotype
(see details)
0086 Cellartis AB Cellartis AB 12/17/2010
BJNhem19
(see details)
0083 Jawaharlal Nehru Centre for Advanced Scientific Research Jawaharlal Nehru Centre for Advanced Scientific Research 12/17/2010
BJNhem20
(see details)
0084 Jawaharlal Nehru Centre for Advanced Scientific Research Jawaharlal Nehru Centre for Advanced Scientific Research 12/17/2010
WIBR4
(see details)
0080 Whitehead Institute for Biomedical Research/Maya Mitalipova Whitehead Institute for Biomedical Research 11/17/2010
WIBR5
(see details)
0081 Whitehead Institute for Biomedical Research/Maya Mitalipova Whitehead Institute for Biomedical Research 11/17/2010
WIBR6
(see details)
0082 Whitehead Institute for Biomedical Research/Maya Mitalipova Whitehead Institute for Biomedical Research 11/17/2010
WIBR3
(see details)
0079 Whitehead Institute for Biomedical Research/Maya Mitalipova Whitehead Institute for Biomedical Research 11/17/2010
Shef 3
(see details)
0077 Centre for Stem Cell Biology University of Sheffield 11/17/2010
Shef 6
(see details)
0078 Centre for Stem Cell Biology University of Sheffield 11/17/2010
HUES 45
(see details)
0076 HSCI iPS Core Harvard University 09/28/2010
WIBR1
(see details)
0074 Whitehead Institute for Biomedical Research/Maya Mitalipova Whitehead Institute for Biomedical Research 06/21/2010
WIBR2
(see details)
0075 Whitehead Institute for Biomedical Research/Maya Mitalipova Whitehead Institute for Biomedical Research 06/21/2010
Endeavour-2
(see details)
0073 Kuldip Sidhu Stem Cell Laboratory, Faculty of medicine, University of New South Wales 06/21/2010
MA135
(see details)
0072 Advanced Cell Technology, Inc. Advanced Cell Technology, Inc. 06/21/2010
CT1
(see details)
0068 University of Connecticut Stem Cell Core UNIVERSITY OF CONNECTICUT SCH OF MED/DNT 06/21/2010
CT2
(see details)
0069 University of Connecticut Stem Cell Core UNIVERSITY OF CONNECTICUT SCH OF MED/DNT 06/21/2010
CT3
(see details)
0070 University of Connecticut Stem Cell Core UNIVERSITY OF CONNECTICUT SCH OF MED/DNT 06/21/2010
CT4
(see details)
0071 University of Connecticut Stem Cell Core UNIVERSITY OF CONNECTICUT SCH OF MED/DNT 06/21/2010
HUES 62
(see details)
0065 HSCI iPS Core Harvard University 06/03/2010
HUES 63
(see details)
0066 HSCI iPS Core Harvard University 06/03/2010
HUES 64
(see details)
0067 HSCI iPS Core Harvard University 06/03/2010
WA07 (H7)
(see details)
0061 WiCell Research Institute WiCell Research Institute 04/27/2010
WA09 (H9)
(see details)
0062 WiCell Research Institute WiCell Research Institute 04/27/2010
WA13 (H13)
(see details)
0063 WiCell Research Institute WiCell Research Institute 04/27/2010
WA14 (H14)
(see details)
0064 WiCell Research Institute WiCell Research Institute 04/27/2010
UCLA 1
(see details)
0058 Steven Peckman University of California, Los Angeles 04/27/2010
UCLA 2
(see details)
0059 Steven Peckman University of California, Los Angeles 04/27/2010
UCLA 3
(see details)
0060 Steven Peckman University of California, Los Angeles 04/27/2010
HUES 48
(see details)
0053 HSCI iPS Core Harvard University 04/27/2010
HUES 49
(see details)
0054 HSCI iPS Core Harvard University 04/27/2010
HUES 53
(see details)
0055 HSCI iPS Core Harvard University 04/27/2010
HUES 65
(see details)
0056 HSCI iPS Core Harvard University 04/27/2010
HUES 66
(see details)
0057 HSCI iPS Core Harvard University 04/27/2010
MFS5; disease-specific mutation
(see details)
0052 Eric Chiao Stanford University 04/27/2010
NYUES1
(see details)
0045 Christoph Hansis, MD, PhD New York University School of Medicine 03/29/2010
NYUES2
(see details)
0046 Christoph Hansis, MD, PhD New York University School of Medicine 03/29/2010
NYUES3
(see details)
0047 Christoph Hansis, MD, PhD New York University School of Medicine 03/29/2010
NYUES4
(see details)
0048 Christoph Hansis, MD, PhD New York University School of Medicine 03/29/2010
NYUES5
(see details)
0049 Christoph Hansis, MD, PhD New York University School of Medicine 03/29/2010
NYUES6
(see details)
0050 Christoph Hansis, MD, PhD New York University School of Medicine 03/29/2010
NYUES7
(see details)
0051 Christoph Hansis, MD, PhD New York University School of Medicine 03/29/2010
UCSF4
(see details)
0044 Susan Fisher University of California San Francisco 03/12/2010
WA01 (H1)
(see details)
0043 WiCell Research Institute WiCell Research Institute 01/29/2010
CyT49
(see details)
0041   ViaCyte, Inc. 01/19/2010
Rockefeller University Embryonic Stem Cell Line 3 (RUES3)
(see details)
0042 The Rockefeller University, Ali Brivanlou The Rockefeller University 01/19/2010
HUES 1
(see details)
0014 HSCI iPS Core Harvard University 12/14/2009
HUES 10
(see details)
0023 HSCI iPS Core Harvard University 12/14/2009
HUES 11
(see details)
0024 HSCI iPS Core Harvard University 12/14/2009
HUES 12
(see details)
0025 HSCI iPS Core Harvard University 12/14/2009
HUES 13
(see details)
0026 HSCI iPS Core Harvard University 12/14/2009
HUES 14
(see details)
0027 HSCI iPS Core Harvard University 12/14/2009
HUES 15
(see details)
0028 HSCI iPS Core Harvard University 12/14/2009
HUES 16
(see details)
0029 HSCI iPS Core Harvard University 12/14/2009
HUES 17
(see details)
0030 HSCI iPS Core Harvard University 12/14/2009
HUES 18
(see details)
0031 HSCI iPS Core Harvard University 12/14/2009
HUES 19
(see details)
0032 HSCI iPS Core Harvard University 12/14/2009
HUES 2
(see details)
0015 HSCI iPS Core Harvard University 12/14/2009
HUES 20
(see details)
0033 HSCI iPS Core Harvard University 12/14/2009
HUES 21
(see details)
0034 HSCI iPS Core Harvard University 12/14/2009
HUES 22
(see details)
0035 HSCI iPS Core Harvard University 12/14/2009
HUES 23
(see details)
0036 HSCI iPS Core Harvard University 12/14/2009
HUES 24
(see details)
0037 HSCI iPS Core Harvard University 12/14/2009
HUES 26
(see details)
0038 HSCI iPS Core Harvard University 12/14/2009
HUES 27
(see details)
0039 HSCI iPS Core Harvard University 12/14/2009
HUES 28
(see details)
0040 HSCI iPS Core Harvard University 12/14/2009
HUES 3
(see details)
0016 HSCI iPS Core Harvard University 12/14/2009
HUES 4
(see details)
0017 HSCI iPS Core Harvard University 12/14/2009
HUES 5
(see details)
0018 HSCI iPS Core Harvard University 12/14/2009
HUES 6
(see details)
0019 HSCI iPS Core Harvard University 12/14/2009
HUES 7
(see details)
0020 HSCI iPS Core Harvard University 12/14/2009
HUES 8
(see details)
0021 HSCI iPS Core Harvard University 12/14/2009
HUES 9
(see details)
0022 HSCI iPS Core Harvard University 12/14/2009
Rockefeller University Embryonic Stem Cell Line 1 (RUES1)
(see details)
0012 The Rockefeller University, Ali Brivanlou The Rockefeller University 12/02/2009
Rockefeller University Embryonic Stem Cell Line 2 (RUES2)
(see details)
0013 The Rockefeller University, Ali Brivanlou The Rockefeller University 12/02/2009
CHB-1
(see details)
0001 On Hold ** George Q. Daley, M.D., Ph.D. Children's Hospital Corporation 12/02/2009
CHB-10
(see details)
0009 George Q. Daley, M.D., Ph.D. Children's Hospital Corporation 12/02/2009
CHB-11
(see details)
0010 George Q. Daley, M.D., Ph.D. Children's Hospital Corporation 12/02/2009
CHB-12
(see details)
0011 George Q. Daley, M.D., Ph.D. Children's Hospital Corporation 12/02/2009
CHB-2
(see details)
0002 On Hold ** George Q. Daley, M.D., Ph.D. Children's Hospital Corporation 12/02/2009
CHB-3
(see details)
0003 On Hold ** George Q. Daley, M.D., Ph.D. Children's Hospital Corporation 12/02/2009
CHB-4
(see details)
0004 George Q. Daley, M.D., Ph.D. Children's Hospital Corporation 12/02/2009
CHB-5
(see details)
0005 George Q. Daley, M.D., Ph.D. Children's Hospital Corporation 12/02/2009
CHB-6
(see details)
0006 George Q. Daley, M.D., Ph.D. Children's Hospital Corporation 12/02/2009
CHB-8
(see details)
0007 George Q. Daley, M.D., Ph.D. Children's Hospital Corporation 12/02/2009
CHB-9
(see details)
0008 George Q. Daley, M.D., Ph.D. Children's Hospital Corporation 12/02/2009

Total Eligible Lines = 283

* NIH Registration Number:

The NIH registration number should be used on all NIH competing applications and annual progress reports to identify the stem cell line proposed for use. Identify the specific line(s) from the Registry using the NIH Registration Number (e.g., 0001), in the specified location in the application:

  • For grant applications using the SF424(R&R) electronic application packages, section 4 of the PHS398 Cover Page Supplement component provides fields in which to identify approved cell lines.
  • For grant applications using the SF424(R&R) Individual Fellowship electronic application packages, section C of the PHS Fellowship Supplemental Form component provides fields in which to identify approved cell lines.
  • For grant applications using the PHS 398 paper application form, the Human Embryonic Stem Cells section on page 3 provides a location in which to identify approved cell lines.

** On Hold - NIH has received public comment on a proposed change to the definition of “human embryonic stem cells” in the NIH Guidelines for Human Stem Cell Research. While NIH is considering those public comments on the proposed change, this hESC line is currently on hold and should not be used in NIH-funded research. If grantees are currently using any of these lines they may contact the NIH Institute or Center that is funding their project for further information.


Go to NIH Form 2890 Login Page

Go to NIH Stem Cell Information Page


   
Related Resources

    NIH Form 2890:

  • Login Page
    (Authorization Required)
    Contact Us:

  • Email questions to:
    hescregistry@mail.nih.gov

  • (Emails that are offensive or unrelated to stem cells will be deleted.)
 

This page last updated on July 13, 2011
Content Manager: stemcell@mail.nih.gov 
Technical Issues: E-mail OER Webmaster